BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37020390)

  • 1. The prognostic value and biological functions of
    Ying Y; Meng Y; Bian L; Zhang M; Zhou P; Zhang S; Wang W; Yao Y; Ren Q; Li D
    Epigenomics; 2023 Feb; 15(3):147-166. PubMed ID: 37020390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
    Li J; Lu M; Jin J; Lu X; Xu T; Jin S
    Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association analysis between HFM1 variation and primary ovarian insufficiency in Chinese women.
    Pu D; Wang C; Cao J; Shen Y; Jiang H; Liu J; Wu BL; Zhang W; Wu J
    Clin Genet; 2016 May; 89(5):597-602. PubMed ID: 26679638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression.
    Lv Q; Guan S; Zhu M; Huang H; Wu J; Dai X
    Technol Cancer Res Treat; 2021; 20():15330338211004935. PubMed ID: 33783288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-489 Confines Uncontrolled Estrogen Signaling through a Negative Feedback Mechanism and Regulates Tamoxifen Resistance in Breast Cancer.
    Soni M; Saatci O; Gupta G; Patel Y; Keerthi Raja MR; Li J; Liu X; Xu P; Wang H; Fan D; Sahin O; Chen H
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance.
    Gwak JM; Kim M; Kim HJ; Jang MH; Park SY
    Oncotarget; 2017 May; 8(22):36305-36318. PubMed ID: 28422735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.
    Bekele RT; Venkatraman G; Liu RZ; Tang X; Mi S; Benesch MG; Mackey JR; Godbout R; Curtis JM; McMullen TP; Brindley DN
    Sci Rep; 2016 Feb; 6():21164. PubMed ID: 26883574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
    Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
    BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FE65 defines the efficacy of tamoxifen treatment via osteopontin expression in estrogen receptor-positive breast cancer.
    Xu J; Iwabuchi E; Miki Y; Kanai A; Takagi K; Suzuki T; Ishida T; Sasano H
    Pathol Res Pract; 2022 Jun; 234():153898. PubMed ID: 35447603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of TRAF4 predicts poor prognosis in tamoxifen-treated breast cancer and promotes tamoxifen resistance.
    Zhou J; Li W; Ming J; Yang W; Lu L; Zhang Q; Ruan S; Huang T
    Anticancer Drugs; 2020 Jul; 31(6):558-566. PubMed ID: 32304412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in DNA Damage Repair Gene Expression and Cell Cycle Gene Expression Do Not Explain Radioresistance in Tamoxifen-Resistant Breast Cancer.
    Post AEM; Bussink J; Sweep FCGJ; Span PN
    Oncol Res; 2020 Feb; 28(1):33-40. PubMed ID: 31046897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
    Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
    Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.
    McClaine RJ; Marshall AM; Wagh PK; Waltz SE
    Neoplasia; 2010 Aug; 12(8):650-8. PubMed ID: 20689759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in tamoxifen-treated breast cancer patients.
    Jahangiri R; Jamialahmadi K; Gharib M; Emami Razavi A; Mosaffa F
    Gene; 2019 Feb; 685():24-31. PubMed ID: 30359738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.